Teriflunomide topical pharmaceutical compositions
The present invention relates to a novel topical pharmaceutical composition of Teriflunomide, comprising teriflunomide or its pharmaceutically acceptable salt in combination with pharmaceutically acceptable excipients, wherein the said composition is effective for use in treatment of pain associated with disorders like inflammation and arthritis. The composition is also useful for relieving the symptoms of pain and arthritis in subjects suffering from autoimmune diseases like multiple sclerosis or rheumatoid arthritis. The said topical composition of teriflunomide is prepared in the form of topical gel, topical cream, topical ointment, topical solution, lotion or topical spray with significantly enhanced permeability and diffusion rate of the drug.
1. A topical pharmaceutical composition of
(i) teriflunomide or its pharmaceutically acceptable salt in an amount of 0.5% to 10% by weight of the composition;
(ii) a carrier comprising waterer;
(iii) a permeation enhancer; and
(iv) at least one pharmaceutically acceptable excipient;
wherein the teriflunomide or its pharmaceutically acceptable salt to the permeation enhancer is in a weight ratio of 1:1 to 1:20.
2. The topical pharmaceutical composition as claimed in claim 1 , wherein the excipient is selected from the group comprising solvents, co-solvents, emulsifiers, co-emulsifiers, solubilizers, preservatives, thickeners, pH modifiers, buffers, diluents, coolants, counter-irritants, surfactants, oil-phase components, aqueous phase components, anti-oxidants, moisturisers, lubricants, stabilizers and other topical excipients.
3. The topical pharmaceutical composition as claimed in claim 1 , wherein the excipient is a lipophilic component or a hydrophilic component.
4. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition is in the form of a cream, a lotion, an ointment, a gel, a spray, a liniment, or a solution.
5. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition comprises teriflunomide or its pharmaceutically acceptable salt in the range of 0.5% to 5% by weight of the composition.
6. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition comprises the teriflunomide or its pharmaceutically acceptable salt to the permeation enhancer in a weight ratio of 1:1 to 1:10.
7. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition has a pH in the range between 3 and 8.
8. A topical pharmaceutical composition as claimed in claim 1 , further comprising one or more active ingredients selected from the group consisting of
a) COX inhibitors;
b) Corticosteroids;
c) Immuno-suppressants;
d) Counter-irritants; and
e) Antihistaminic agents.
9. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition is in the form of a cream.
10. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition is in the form of a lotion.
11. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition has a pH in the range between 4.5 and 7.5.
12. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition has a pH in the range between 5.0 and 6.5.
13. The topical pharmaceutical composition as claimed in claim 1 , wherein the composition has a pH of about 5.5.
14. The topical pharmaceutical composition as claimed in claim 1 , wherein the permeation enhancer comprises dimethyl sulfoxide.
15. A process for the preparation of the topical pharmaceutical composition as claimed in claim 1 , comprising the following steps:
i. combining an oily phase including an oil phase component with an aqueous phase including an aqueous phase component to provide a first mixture;
ii. combining a second mixture comprising teriflunomide or its pharmaceutically acceptable salt and a carrier or a permeation enhancer with the first mixture to form the composition;
iii. optionally adding one or more preservatives to the composition;
iv. optionally adding one or more gelling agents to the composition;
V. optionally adjusting the pH of the composition with a pH adjusting agent; and
vi. wherein at least one of the oily phase, the aqueous phase, and the second mixture further comprises the at least one pharmaceutically acceptable excipient.
16. The process as claimed in claim 15 , wherein at least one of the oily phase or aqueous phase further comprises an emulsifier.
17. The process as claimed in claim 15 , further comprising adjusting the pH of the composition with a pH adjusting agent.
18. A topical pharmaceutical composition of
(i) teriflunomide or its pharmaceutically acceptable salt;
(ii) a carrier comprising water;
(iii) a permeation enhancer; and
(iv) at least one pharmaceutically acceptable excipient;
wherein the teriflunomide or its pharmaceutically acceptable salt to the permeation enhancer is in a weight ratio of 1:1 to 1:10.
19. A topical pharmaceutical composition of
(i) teriflunomide or its pharmaceutically acceptable salt in an amount of 0.5% to 15% by weight of the composition;
(ii) a carrier comprising water;
(iii) optionally a permeation enhancer; and
(iv) at least one pharmaceutically acceptable excipient;
wherein the teriflunomide or its pharmaceutically acceptable salt to the carrier is in a weight ratio of 1:1 to 1:20.